Bevacizumab plus erlotinib is active in the treatment of patients with carcinomas of unknown primary site

By  

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer

By Boku Narikazu   Muro Kei   Machida Nozomu   Hashigaki Satoshi   Kimura Nobuyuki   Suzuki Mie   Lechuga Mariajose   Miyata Yoshinori  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 261-270

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

By Morgan Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 723-728

Springer Publishing Company

Access to resources Recommend Favorite

Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer

By Kang Byung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1671-1675

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite